Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis

Kay Wang, Jan Y. Verbakel, Jason Oke, Alexander Fleming-Nouri, Josh Brewin, Nia Roberts, Norihiro Harada, Ryo Atsuta, Kazuhisa Takahashi, Kazutaka Mori, Tomoyuki Fujisawa, Toshihiro Shirai, Tomotaka Kawayama, Hiromasa Inoue, Stephen Lazarus, Stanley Szefler, Fernando Martinez, Dominick Shaw, Ian D. Pavord, Mike Thomas
European Respiratory Journal 2020 55: 1902150; DOI: 10.1183/13993003.02150-2019
Kay Wang
1Nuffield Dept of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kay.wang@phc.ox.ac.uk
Jan Y. Verbakel
2KU Leuven, Dept of Public Health and Primary Care, Leuven, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Oke
1Nuffield Dept of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Fleming-Nouri
3Oxford University Clinical Academic Graduate School, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josh Brewin
1Nuffield Dept of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nia Roberts
4Bodleian Health Care Libraries, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norihiro Harada
5Dept of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Norihiro Harada
Ryo Atsuta
5Dept of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuhisa Takahashi
5Dept of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazutaka Mori
6Second Division Dept of Internal Medicine, Hamamatsu University School of Medicine, Hammamatsu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomoyuki Fujisawa
6Second Division Dept of Internal Medicine, Hamamatsu University School of Medicine, Hammamatsu, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tomoyuki Fujisawa
Toshihiro Shirai
7Dept of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomotaka Kawayama
8Division of Respirology, Neurology, and Rheumatology, Kurume University School of Medicine, Kurume, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiromasa Inoue
9Dept of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Lazarus
10Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stanley Szefler
11Children's Hospital Colorado, The Breathing Institute, Dept of Pediatrics, University of Colorado School of Medicine, Anschutz Medical Campus, Aurora, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fernando Martinez
12Asthma and Airway Disease Research Center, University of Arizona, Tucson, AZ, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dominick Shaw
13Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dominick Shaw
Ian D. Pavord
14Oxford Respiratory NIHR BRC and Respiratory Medicine Unit, Nuffield Dept of Medicine, University of Oxford, Oxford, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike Thomas
15Primary Care, Population Sciences and Medical Education (PPM), University of Southampton, Southampton, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mike Thomas
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background High exhaled nitric oxide fraction (FENO) levels are associated with greater risk of asthma exacerbation. However, it is not clear how FENO can be used to guide safe reductions in inhaled corticosteroid (ICS) doses in asthma patients. This study assesses the ability of FENO to guide ICS reductions.

Methods Systematic searching of electronic databases identified prospective observational studies and randomised controlled trials which recruited participants with mild-to-moderate asthma aged ≥12 years and measured FENO before reducing ICS. We performed multilevel mixed-effects logistic regression in relation to acute exacerbations and estimated each participant's exacerbation risk using our logistic regression model.

Results We included data from seven out of eight eligible studies, representing 384 participants. ICS doses were halved in four studies and withdrawn in three studies. A baseline FENO measurement of ≥50 ppb was associated with increased risk of exacerbations (crude OR 3.14, 95% CI 1.41–7.00, p=0.005; adjusted OR 3.08, 95% CI 1.36–6.98, p=0.007) and corresponded to an estimated exacerbation risk cut-off of 15%. Reducing ICS when estimated exacerbation risk was <15% versus <10% would result in fewer patients remaining on the same ICS dose (40 (10.4%) out of 384 versus 141 (36.7%) out of 384), but similar proportions of patients avoiding exacerbations (222 (91.4%) out of 243, 95% CI 87.1–94.6% versus 311 (90.4%) out of 344, 95% CI 86.8–93.3%).

Conclusion In patients with mild-to-moderate asthma, gradual ICS reduction when FENO is <50 ppb may help decrease ICS use without increasing exacerbations. Future research should aim to validate these findings in larger populations.

Abstract

In nonsmoking patients with mild-to-moderate well-controlled asthma, stepping down treatment when FENO is <50 ppb reduces prescribing of inhaled corticosteroids without increasing exacerbations http://bit.ly/2SKaxSt

Footnotes

  • This article has an editorial commentary: https://doi.org/10.1183/13993003.01319-2020

  • This article has supplementary material available from erj.ersjournals.com

  • Ethical approval: Overall ethical approval was not required as this study did not require use of patient identifiers. Collaborating groups obtained individual approvals for data sharing from Research Ethics Committees at Juntendo University, Kinki University Hospital, Keio University Hospital, Kagoshima University Medical and Dental Hospital and Shizuoka General Hospital.

  • Conflict of interest: K. Wang reports grants from National Institute for Health Research, during the conduct of the study.

  • Conflict of interest: J.Y. Verbakel has nothing to disclose.

  • Conflict of interest: J. Oke has nothing to disclose.

  • Conflict of interest: A. Fleming-Nouri has nothing to disclose.

  • Conflict of interest: J. Brewin has nothing to disclose.

  • Conflict of interest: N. Roberts has nothing to disclose.

  • Conflict of interest: N. Harada reports personal fees from AstraZeneca, outside the submitted work. In addition, N. Harada has a patent Japanese Patent Application 2018-097070 pending.

  • Conflict of interest: R. Atsuta has nothing to disclose.

  • Conflict of interest: K. Takahashi reports grants and personal fees from Chugai Pharmaceutical Co., Ltd, grants and personal fees from Nippon Boehringer Ingelheim Co., Ltd, grants and personal fees from MSD K.K., grants from GlaxoSmithKline Consumer Healthcare Japan K.K., grants from Nippon Shinyaku Co., Ltd, grants from Tsumura & Co., grants and personal fees from Pfizer Inc., grants and personal fees from AstraZeneca K.K., grants and personal fees from Taiho Pharmaceutical Co., Ltd, grants from Astellas Pharma Inc., grants and personal fees from Kyorin Pharmaceutical Co., Ltd, grants from Kyowa Hakko Kirin Co., Ltd, grants and personal fees from Teijin Pharma Limited, grants from Mochida Pharmaceutical Co., Ltd, grants from Toyama Chemical Co., Ltd, grants from Sanofi K.K., grants and personal fees from Ono Pharmaceutical Co., Ltd, grants and personal fees from Nobelpharma Co., Ltd, grants and personal fees from Novartis Pharma K.K., grants from Shionogi & Co., Ltd, grants and personal fees from Eli Lilly Japan K.K., grants from Nipro Corporation, grants from Torii Pharmaceutical Co., Ltd, grants from MiZ Company Limited, personal fees from Sumitomo Dainippon Pharma Co., Ltd, personal fees from Bristol-Myers K.K., personal fees from Meiji Seika Pharma Co., Ltd, personal fees from Otsuka Pharmaceutical Co., Ltd, personal fees from Parexel International Corporation, personal fees from Eisai Co., Ltd, personal fees from Mitsubishi Tanabe Pharma, outside the submitted work.

  • Conflict of interest: K. Mori has nothing to disclose.

  • Conflict of interest: T. Fujisawa has nothing to disclose.

  • Conflict of interest: T. Shirai has nothing to disclose.

  • Conflict of interest: T. Kawayama has nothing to disclose.

  • Conflict of interest: H. Inoue reports grants from Astellas, AstraZeneca, Boehringer-Ingelheim, Chugai Pharm, GlaxoSmithKline, Pfizer, Merck Sharp & Dohme, Novartis, Teijin-Pharma, personal fees from Astellas, AstraZeneca, Boehringer-Ingelheim, Chugai Pharm, GlaxoSmithKline, Kyorin, Merck Sharp & Dohme, Meiji Seika Pharma, Novartis, Otsuka, Pfizer, Taiho, outside the submitted work.

  • Conflict of interest: S. Lazarus reports grants from NIH/NHLBI, during the conduct of the study; grants from NIH/NHLBI, grants from American Lung Association – Airway Clinical Research Centers Network (ALA-ACRC), outside the submitted work.

  • Conflict of interest: S. Szefler reports other from Boehringer-Ingelheim, other from Genentech, other from GlaxoSmithKline, other from AstraZeneca, other from Daiichi Sankyo, grants from GlaxoSmithKline, other from Propeller Health, other from Sanofi, other from Regeneron, outside the submitted work.

  • Conflict of interest: F. Martinez reports grants from NIH/NHLBI, grants from NIH/NIEHS, grants from NIH/NIAID, grants from NIH/Office of Director, grants from Johnson & Johnson, personal fees from Copeval, personal fees from Commense Inc, outside the submitted work.

  • Conflict of interest: D. Shaw reports personal fees from AstraZeneca, GSK, TEVA and Novartis, outside the submitted work.

  • Conflict of interest: I.D. Pavord reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Aerocrine, personal fees from Almirall, personal fees from Novartis, personal fees from GlaxoSmithKline, personal fees from Genentech, personal fees from Regeneron, speakers’ fees from Teva, speakers’ fees from Chiesi, advisory board fees from Sanofi, advisory board fees from Circassia, advisory board fees from Knopp, grants from NIHR, outside the submitted work.

  • Conflict of interest: M. Thomas reports personal fees from GSK, personal fees from Novartis, personal fees from Boehringer Ingelheim, outside the submitted work; and recent membership of the BTS SIGN Asthma guideline steering group and the NICE Asthma Diagnosis and Monitoring guideline development group.

  • Support statement: This paper presents independent research funded by the National Institute for Health Research under its Postdoctoral Fellowship Programme (grant reference number PDF-2016-09-007). Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received November 5, 2019.
  • Accepted February 13, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 55 Issue 5 Table of Contents
European Respiratory Journal: 55 (5)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis
Kay Wang, Jan Y. Verbakel, Jason Oke, Alexander Fleming-Nouri, Josh Brewin, Nia Roberts, Norihiro Harada, Ryo Atsuta, Kazuhisa Takahashi, Kazutaka Mori, Tomoyuki Fujisawa, Toshihiro Shirai, Tomotaka Kawayama, Hiromasa Inoue, Stephen Lazarus, Stanley Szefler, Fernando Martinez, Dominick Shaw, Ian D. Pavord, Mike Thomas
European Respiratory Journal May 2020, 55 (5) 1902150; DOI: 10.1183/13993003.02150-2019

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Using fractional exhaled nitric oxide to guide step-down treatment decisions in patients with asthma: a systematic review and individual patient data meta-analysis
Kay Wang, Jan Y. Verbakel, Jason Oke, Alexander Fleming-Nouri, Josh Brewin, Nia Roberts, Norihiro Harada, Ryo Atsuta, Kazuhisa Takahashi, Kazutaka Mori, Tomoyuki Fujisawa, Toshihiro Shirai, Tomotaka Kawayama, Hiromasa Inoue, Stephen Lazarus, Stanley Szefler, Fernando Martinez, Dominick Shaw, Ian D. Pavord, Mike Thomas
European Respiratory Journal May 2020, 55 (5) 1902150; DOI: 10.1183/13993003.02150-2019
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • Asthma medication in obese and healthy weight asthma
  • The impact of COVID-19 on patients with asthma
  • FEV1 decline and cardiovascular disease in COPD
Show more Original Articles

Asthma

  • Asthma medication in obese and healthy weight asthma
  • Cost-effectiveness of azithromycin in reducing asthma exacerbations
  • Complement C3 and allergic asthma
Show more Asthma

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society